SS-31 Cycle Length: How Long Do Research Protocols Last?

A typical SS-31 cycle length is 4 to 12 weeks of daily dosing in published research, and some clinical trials have run for 24 weeks. Community self-experimenters usually stop at 4 to 8 weeks and then take a 2- to 4-week washout. SS-31 is not FDA-approved for human use, so there is no official cycle length — only research protocols and anecdotal reports.

What SS-31 (Elamipretide) Actually Is

SS-31 is the research name for elamipretide, a synthetic tetrapeptide that concentrates in the inner mitochondrial membrane and binds to cardiolipin. The two names refer to the same molecule.

Researchers have studied elamipretide in Barth syndrome, primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration. The peptide is sold online as a research chemical labeled as being for laboratory research only.

SS-31 is not FDA-approved for human use in the United States, and it is not available by prescription at any pharmacy.

How Long Is a Typical SS-31 Cycle?

Reported SS-31 cycle lengths cluster into a few ranges, and the right duration depends on the research question being asked.

• 4 weeks: common in early tolerability and pharmacokinetic work.
• 8 weeks: a frequent middle ground in community logs.
• 12 weeks: used in the Barth syndrome program and several cardiac studies.
• 24 weeks: the primary endpoint window in a mitochondrial myopathy trial.

In self-reported use, most people describe 4 to 8 weeks on, followed by a break. Longer runs happen, but they are usually monitored inside a trial rather than at home.

Setting	Typical cycle length	Dosing frequency	Notes
Early-phase clinical trials	4 weeks	Daily subcutaneous	Focus on safety and blood levels
Barth syndrome trials	12 weeks, then open-label extension	Daily subcutaneous	Long-term follow-up collected
Mitochondrial myopathy trials	24 weeks	Daily subcutaneous	Primary endpoint measured at week 24
Community self-experiment	4–8 weeks	Daily, or 5 days on / 2 off	No clinical standard exists

Why Daily Dosing Drives Shorter Cycles

Elamipretide has a short plasma half-life, so research protocols usually dose once daily by subcutaneous injection. Because injections are daily, cycle length is often limited by convenience and injection-site tolerance rather than by a target blood level.

Some protocols use a fixed milligram dose, while others scale by body weight in milligrams per kilogram. That difference makes it hard to compare one person's SS-31 cycle length directly with another's.

Community logs sometimes use a 5-days-on, 2-days-off pattern to reduce injection burden. There is no controlled data showing that this schedule matches daily dosing.

Stacking SS-31 With Other Mitochondrial Peptides

SS-31 is frequently discussed alongside MOTS-c because both target mitochondrial function through different pathways. A commonly described ss-31 and mots-c protocol pairs 4 to 8 weeks of SS-31 with a similar-length MOTS-c run, then a washout of 2 to 4 weeks.

People who run ss-31 and mots-c together often stagger the start dates by a week or two so they can tell which compound is responsible for any effect. That is a practical idea, not a validated method.

Stacking research peptides increases the number of unknowns. Interactions between SS-31 and MOTS-c have not been formally studied in humans.

How SS-31 Cycle Length Compares With Other Peptides

Cycle length varies widely across the research peptide market, which makes cross-comparison confusing.

Peptide	Common reported cycle length	Typical route
SS-31 (elamipretide)	4–12 weeks	Subcutaneous
MOTS-c	4–8 weeks	Subcutaneous
AOD 9604	8–12 weeks	Subcutaneous
Kisspeptin-10	2–6 weeks	Subcutaneous
Selank	2–4 weeks	Intranasal or subcutaneous

Anyone comparing an aod 9604 cycle length with SS-31 should note that AOD 9604 is studied for fat metabolism, a completely different target. The same caution applies to a kisspeptin-10 cycle length, which is usually short because of hormonal feedback, and to a selank cycle length, which is typically measured in weeks rather than months.

SS-31 Side Effects and Safety Considerations

Reported ss-31 peptide side effects in trials have mostly been mild: injection-site reactions, headache, dizziness, and occasional nausea. Serious events have been uncommon, but trials are run under medical supervision with pharmaceutical-grade material.

A balanced look at ss-31 peptide benefits and side effects has to acknowledge that most human data come from specific disease populations, not healthy adults. Results in Barth syndrome or mitochondrial myopathy do not automatically transfer to general use.

SS-31 has failed to win FDA approval for its lead indication, and no regulatory agency has cleared it as a treatment. Anyone using it outside a trial is doing so without established safety data.

Sourcing, Purity, and Storage

People who search for ss-31 peptide buy online should look for a third-party certificate of analysis showing purity above 98% and a batch number that matches the vial. Unverified vendors are the most common source of poor-quality product.

Lyophilized SS-31 should be stored frozen, typically at -20°C, and reconstituted vials kept refrigerated and used within the timeframe the supplier specifies. Freeze-thaw cycles degrade peptides.

Key Takeaways on SS-31 Cycle Length

• The most common SS-31 cycle length in research is 4 to 12 weeks of daily subcutaneous dosing.
• Clinical trials have run as long as 24 weeks, always with monitoring.
• Community users typically cycle 4 to 8 weeks on and 2 to 4 weeks off.
• SS-31 is not FDA-approved for human use in the United States.
• No validated protocol exists for stacking SS-31 with MOTS-c or any other peptide.
• Talk to a healthcare professional before using any research peptide, and never replace prescribed treatment with one.

COMMON QUESTIONS

Frequently Asked Questions

How long should an SS-31 cycle be?

Most published SS-31 research runs 4 to 12 weeks of daily subcutaneous dosing, and one large myopathy trial used a 24-week endpoint. Community users typically report 4 to 8 weeks on followed by a washout. Because SS-31 is not FDA-approved, no official cycle length exists.

Do you need to cycle off SS-31?

There is no clinical guidance on cycling off SS-31 because it has never been approved for human use. Self-experimenters commonly take 2 to 4 weeks off between cycles, but that pattern comes from anecdote, not controlled data. Any decision about duration or breaks should be discussed with a healthcare professional.

Is SS-31 legal to buy in the United States?

SS-31 is sold legally only as a research chemical for laboratory use, not as a supplement or medication. It is not FDA-approved for human use and cannot be prescribed by a doctor. Buying it from an unverified vendor also carries a real risk of low purity or mislabeled product.